New Project on semaglutide and bones
A new project named SOBER II is aimed to investigate whether GLP-1-like drugs (semaglutide) also have a beneficial effect on bones
New Project at the Department of Endocrinology M, OUH and KMEB.
The project SOBER II will investigate whether GLP-1-like drugs (semaglutide), which are already approved for the treatment of type 2 diabetes, also have a beneficial effect on bones. Studies suggest that drugs that mimic the gut hormone GLP-1, used for the treatment of type 2 diabetes and obesity, may have positive effects on bones. The aim of this trial is to investigate if semaglutide, a long-acting GLP-1RA, improves bone formation and strength in men and women aged 50-85 years with T2D and low bone mass.
Treatment involves oral administration of semaglutide once daily or matching placebo. The primary outcome is bone formation assessed using a circulating serum biomarker, and the secondary outcomes are biomarker of bone resorption, bone mineral density at the hip and lumbar spine assess by bone scans, bone microstructure, and bone remodelling. The duration of the trial is 52 weeks.
The project is led by MD and PhD students Julie Bjerrelund and Morten Svarer Hansen, and they have started recruiting participants.
The project aims to contribute knowledge about the effects of semaglutide on bones in people with type 2 diabetes. If it turns out that semaglutide is beneficial for bones, it will be particularly attractive to use in individuals with type 2 diabetes who are also at high risk for fractures.